Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation studySeth E. Karol, Jeffrey E. Rubnitz, Paul E. Mead et al.|The Lancet Oncology|2020Cited by 167
NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cellsSteven W. Paugh, William E. Evans, Erik Bonten et al.|Nature Genetics|2015Cited by 162
Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed TherapySima Jeha, Ching‐Hon Pui, John Choi et al.|Blood Cancer Discovery|2021Cited by 162
Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemiaSeth E. Karol, Mary V. Relling, Wenjian Yang et al.|Blood|2015Cited by 121